Mark Manfredi

CEO Ikena Oncology

[Ikena Oncology @IkenaOncology]

$IKNA management team will participate in three investor conferences in November: the @Stifel Healthcare Conference, @Jefferies London Healthcare Conference, and @Piper_Sandler 35th Annual Healthcare Conference. Read press release for more details: https://t.co/PtzQ3ZzZLK

[Ikena Oncology @IkenaOncology]

Happy #FourthofJuly to everyone celebrating! From all of us at Ikena Oncology, enjoy the celebrations and have a fantastic day of #Independence and #Unity.

[Mark Manfredi @markgmanfredi]

Great progress on demonstrating the promise of the Hippo pathway. Thrilled that we were able to share our differentiated strategy with IK-930 at AACR this week. Exciting times!

[Ikena Oncology @IkenaOncology]

Read about the breakout weekend TEAD had at #AACR23 in this @evaluatevantage article by @JacobPlieth, discussing therapies targeting the #HippoPathway and the differentiated TEAD1 selectivity profile for IK-930. Visit: https://t.co/IP95vWn0Za

[Ikena Oncology @IkenaOncology]

Read about the breakout weekend TEAD had at #AACR23 in this @evaluatevantage article by @JacobPlieth, discussing therapies targeting the #HippoPathway and the differentiated TEAD1 selectivity profile for IK-930. Visit: https://t.co/IP95vWn0Za

[Ikena Oncology @IkenaOncology]

We're excited to share more data on IK-930’s differentiation as a novel, paralog-selective TEAD inhibitor at the upcoming @AACR Annual Meeting 2023 on April 14-19 in two posters – join us in Orlando to check it out! For more information, visit: https://t.co/CJltxsQVmP #AACR23

[Mark Manfredi @markgmanfredi]

Very proud of the Ikena team for the progress across our pipeline from delivery of clinical data on IK-175 in bladder cancer, dose escalation of our TEAD inhibitor IK-930 and the nomination of the MEK/RAF complex inhibitor IK-595.

[Ikena Oncology @IkenaOncology]

We’re excited to share our Q4 and full year 2022 financial results and corporate update highlighting advancements across our entire pipeline of targeted oncology programs. Read our full press release for more details: https://t.co/CtudqZzkIE

[Ikena Oncology @IkenaOncology]

#ICYMI our Chief Scientific Officer, Michelle Zhang, Ph.D., presented preclinical data on our best-in-class #NextGeneration MEK-RAF complex inhibitor, IK-595, at #AACRras23 special conference. To view Dr. Zhang’s presentation, visit: https://t.co/XGM3iMY6o8

[Ikena Oncology @IkenaOncology]

On #InternationalWomensDay, Ikena celebrates the strength, resilience, and achievements of women everywhere. We're proud to support the progress and success of women in #oncology & we're committed to creating a more inclusive and equitable future for all. #IWD2023

[Mark Manfredi @markgmanfredi]

We are excited to continue to disclose the differentiation of IK-595 as a MEK/RAF complex inhibitor at the #AACRras23 meeting.

[Ikena Oncology @IkenaOncology]

We're presenting preclinical data on our best-in-class #NextGeneration MEK-RAF complex inhibitor, IK-595, at #AACRras23 special conference today at 1pm. Don't miss our CSO Michelle Zhang, Ph.D., presenting at a plenary session tomorrow morning at 8am: https://t.co/waPXMgsWcO

[Ikena Oncology @IkenaOncology]

We're excited to share that the @US_FDA has granted Fast Track designation for our novel AHR antagonist, IK-175, in combination with immune checkpoint inhibitors in patients with advanced #UrothelialCarcinoma who have progressed on prior treatment: https://t.co/6tN7wYEbzq

[Mark Manfredi @markgmanfredi]

IK-595 is a differentiated approach to an important complex in the MAPK pathway. Excited for the IND in 2H this year and moving this forward into the clinic!

[Ikena Oncology @IkenaOncology]

Ikena’s development candidate, IK-595, traps MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. To learn more about how Ikena is exploring addressable targets in the RAS signaling pathway visit our website: https://t.co/hL3ykvNf6F

[Mark Manfredi @markgmanfredi]

@JebKeiper @TakedaPharma @NimbusTx Huge congratulations, Jeb and team!

[Ikena Oncology @IkenaOncology]

Today, Ikena announced the company’s first development candidate in the RAS pathway, a next-generation MEK-RAF complex inhibitor, IK-595. For additional development highlights and corporate updates, visit: https://t.co/nrn0hCNjBB

[Ikena Oncology @IkenaOncology]

We’re honored to be recognized as a top life sciences company for @biospace’s 2023 Best Places to Work award! We thank all Ikenians who contribute to making Ikena a top place to work in the life sciences industry. Check out the full list here: https://t.co/eVFcYVFFoU

[Mark Manfredi @markgmanfredi]

Excited to present our initial monotherapy and combination data with IK-175 in urothelial cancer patients that have progressed on multiple lines of therapy including checkpoints. #SITC22!

[Ikena Oncology @IkenaOncology]

Today, we announced initial clinical data in bladder cancer from our ongoing IK-175 clinical program at the Society for Immunotherapy of Cancer (@sitcancer) 2022 Annual Meeting. Read the full press release here: https://t.co/J671VsaHyl #SITC22

[Ikena Oncology @IkenaOncology]

$IKNA shared Q3 2022 financial results, provided a full pipeline update – including updates on our lead targeted oncology program, IK-930, and getting excited for our IK-175 data presentation this week at @sitcancer 2022. Read the full release: https://t.co/ZL0uYlnL9l #SITC22

[Mark Manfredi @markgmanfredi]

Excited to collaborate with AstraZeneca on the potential for our TEAD inhibitor, IK-930 to address therapeutic resistance of osimertinib!

[Ikena Oncology @IkenaOncology]

Today, Ikena provided an update on the differentiation of the company’s lead program in TEAD inhibition and announced its first combination partner for the program, @AstraZeneca. For more details, read our full press release here: https://t.co/TyS6DknU6U

[Mark Manfredi @markgmanfredi]

@KapellerRosana Congratulations, Rosana!

[Ikena Oncology @IkenaOncology]

We are thrilled to announce the launch of the new Ikena website, reflecting our passion and vision of a world in which every #cancer patient has a cure. Visit our website to learn more about how we’re navigating new territory in #TargetedOncology: https://t.co/XB73UX9Vhs

[Ikena Oncology @IkenaOncology]

It is on! Runners have been going since early this morning and passing the baton in stride. Team Ikena is over 40 miles in and going strong at the @RagnarRelay Reach the Beach run!